摘要
目的：比较消化系统肿瘤患者血清ＣＡ５０和ＣＡ１９－９免疫放射分析（ＩＲＭＡ）的诊断价值，探讨ＣＡ５０和ＣＡ１９－９联合检测模式的合理性。方法：ＩＲＭＡ方法检测１４９例消化系统肿瘤患者与对照组血清ＣＡ５０和ＣＡ１９－９，比较分析２项检测结果的关系和临床诊断价值指标。结果：带瘤生存组血清ＣＡ５０和ＣＡ１９－９单独和联合检测的阳性率显著高于术后无瘤组和良性疾病组（Ｐ＜０００５），其中肝和胰腺肿瘤患者的阳性率最高。ＣＡ５０和ＣＡ１９－９单独和联合检测的阳性率差异在各组均无显著性（Ｐ均＞００５）。各组血清ＣＡ５０和ＣＡ１９－９的检测结果呈正相关（Ｐ＜００５）。结论：血清ＣＡ５０和ＣＡ１９－９均可用于消化系统肿瘤的诊断和病情监测。它们的ＩＲＭＡ结果存在正相关关系，联合检测的临床价值并不高于其中一项单独检测。
Purpose: To evaluate the rationality and clinical utili ty of combination assay of serum CA50 and CA19-9 in gastro-intestina l cancers. Methods: Serum CA50 and CA19-9 were determined by IRMA in 149 patients with gastro-intestinal cancer and 156 control subjects. Results: Significantly higher positive rates of serum CA50 and CA19 9 in tumor bearing patients with gastro-intestinal cancer were observe d, compared with the postoperative patients without recurrence or metas tasis and the benign diseases (P<0.005). The values for the two markers were highly correlated (P<0.001), and there have not significant difference between the positive rate of CA50 and CA19-9 (P>0.05). Conclusion: Both CA50 and CA19-9 can be useful tumor markers for diagnosis and follow-up in gastro-intestinal cancer patients, however the joint use does not yield a better diagnostic value than the use of either one alone.
出处
《临床消化病杂志》
2000年第2期51-53,共3页
Chinese Journal of Clinical Gastroenterology
